Literature DB >> 19666061

Adenosine A2a receptor induced gliosis via Akt/NF-kappaB pathway in vitro.

Rong-Hu Ke1, Ji Xiong, Ying Liu, Zhu-Rong Ye.   

Abstract

Gliosis is characterized by increased expression of glial fibrillary acidic protein (GFAP) and astroglial proliferation, although the mechanism underlying the process is still largely undefined. This study explores the role of the adenosine A2a receptor (A2aR) in gliosis after ischemia-like injury in a rat astrocyte cell line transfected with A2aR. A2aR transfection enhanced GFAP expression and cell proliferation. A2aR-selective antagonist Sch58261 decreased GFAP expression in a dose- and time-dependent manner with increased activation of Akt, and induced activation of NF-kappaB. An Akt inhibitor reversed the effect of Sch58261. These results suggest that the effect of A2aR on gliosis is related to the Akt/NF-kappaB signal pathway.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19666061     DOI: 10.1016/j.neures.2009.08.002

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  15 in total

Review 1.  Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

Authors:  Marie Therese Armentero; Annalisa Pinna; Sergi Ferré; José Luis Lanciego; Christa E Müller; Rafael Franco
Journal:  Pharmacol Ther       Date:  2011-07-23       Impact factor: 12.310

2.  Genetic variation in the adenosine regulatory cycle is associated with posttraumatic epilepsy development.

Authors:  Matthew L Diamond; Anne C Ritter; Edwin K Jackson; Yvette P Conley; Patrick M Kochanek; Detlev Boison; Amy K Wagner
Journal:  Epilepsia       Date:  2015-06-04       Impact factor: 5.864

Review 3.  A2A Adenosine Receptor Antagonists in Neurodegenerative Diseases.

Authors:  Stefania Merighi; Pier A Borea; Katia Varani; Fabrizio Vincenzi; Kenneth A Jacobson; Stefania Gessi
Journal:  Curr Med Chem       Date:  2022       Impact factor: 4.740

4.  Adenosine A2A receptor and ecto-5'-nucleotidase/CD73 are upregulated in hippocampal astrocytes of human patients with mesial temporal lobe epilepsy (MTLE).

Authors:  Aurora R Barros-Barbosa; Fátima Ferreirinha; Ângela Oliveira; Marina Mendes; M Graça Lobo; Agostinho Santos; Rui Rangel; Julie Pelletier; Jean Sévigny; J Miguel Cordeiro; Paulo Correia-de-Sá
Journal:  Purinergic Signal       Date:  2016-09-20       Impact factor: 3.765

Review 5.  Adenosinergic signaling in epilepsy.

Authors:  Detlev Boison
Journal:  Neuropharmacology       Date:  2015-09-01       Impact factor: 5.250

Review 6.  From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease?

Authors:  Vanessa Flaten; Cyril Laurent; Joana E Coelho; Ursula Sandau; Vânia L Batalha; Sylvie Burnouf; Malika Hamdane; Sandrine Humez; Detlev Boison; Luísa V Lopes; Luc Buée; David Blum
Journal:  Biochem Soc Trans       Date:  2014-04       Impact factor: 5.407

Review 7.  Astrocytes and Adenosine A2A Receptors: Active Players in Alzheimer's Disease.

Authors:  Cátia R Lopes; Rodrigo A Cunha; Paula Agostinho
Journal:  Front Neurosci       Date:  2021-05-13       Impact factor: 4.677

8.  Association Between Adenosine A2A Receptors and Connexin 43 Regulates Hemichannels Activity and ATP Release in Astrocytes Exposed to Amyloid-β Peptides.

Authors:  Daniela Madeira; Liliana Dias; Patrícia Santos; Rodrigo A Cunha; Paula M Canas; Paula Agostinho
Journal:  Mol Neurobiol       Date:  2021-09-02       Impact factor: 5.590

Review 9.  Having a Coffee Break: The Impact of Caffeine Consumption on Microglia-Mediated Inflammation in Neurodegenerative Diseases.

Authors:  Maria H Madeira; Raquel Boia; António F Ambrósio; Ana R Santiago
Journal:  Mediators Inflamm       Date:  2017-01-31       Impact factor: 4.711

10.  Akt and c-Myc induce stem-cell markers in mature primary p53⁻/⁻ astrocytes and render these cells gliomagenic in the brain of immunocompetent mice.

Authors:  Josefine Radke; Ginette Bortolussi; Axel Pagenstecher
Journal:  PLoS One       Date:  2013-02-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.